EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access

High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus

Ryan T Jarrett iD, Yuri van der Heijden, Matthew S Shotwell, Violet Chihota, Mark A Marzinke iD, Richard E Chaisson, Kelly E Dooley iD, Gavin J Churchyard

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.01297-22 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Ryan T Jarrett und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Arylamine N-Acetyltransferase, HIV Infections, Latent Tuberculosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FIC NIH HHS, NIAID NIH HHS, UNITAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI). Fewer data describe 3HP with dolutegravir-based antiretroviral therapy for the treatment of human immunodeficiency virus (HIV).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arylamine N-AcetyltransferaseHIV InfectionsLatent TuberculosisAdultHumansAntitubercular AgentsBody WeightDrug Therapy, CombinationHIVIsoniazidRifampin

Stichwörter der Autor:innen

3HPHIVN-acetyltransferase 2dolutegravirisoniazidlatent tuberculosis infectionpharmacokineticsrifapentine

Substanzen

Antitubercular AgentsArylamine N-AcetyltransferaseIsoniazidNAT2 protein, humanrifapentineRifampin

Autor:innen und Institutionen

  • Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • The Aurum Institute, Johannesburg, South Africa.
  • Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Departments of Pathology and Medicine (Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Ryan T Jarrett, Mark A Marzinke, Kelly E Dooley

Förderung

  • FIC NIH HHS
  • NIAID NIH HHS
  • UNITAID
  • HHS | NIH | Fogarty International Center
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

Jarrett, R. T., van der Heijden, Y., Shotwell, M. S., Chihota, V., Marzinke, M. A., Chaisson, R. E., Dooley, K. E., & Churchyard, G. J. (2023). High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01297-22

Vancouver

Jarrett RT, van der Heijden Y, Shotwell MS, Chihota V, Marzinke MA, Chaisson RE, et al. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.01297-22

BibTeX
@article{Jarrett2023,
  author = {Jarrett, Ryan T and van der Heijden, Yuri and Shotwell, Matthew S and Chihota, Violet and Marzinke, Mark A and Chaisson, Richard E and Dooley, Kelly E and Churchyard, Gavin J},
  title = {High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.01297-22}
}
Kostenlos starten →